Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Medartis Holding AG, CH0386200239

Medartis Holding AG, CH0386200239

23.04.2021 - 17:49:36

EQS-Adhoc: Medartis Holding AG : Annual General Meeting approves all proposals of the Board of Directors and elects Marco Gadola as the new Chairman of the Board of Directors

Medartis Holding AG Hochbergerstrasse 60E CH-4057 Basel

PRESS RELEASE

Annual General Meeting approves all proposals of the Board of Directors and elects Marco Gadola as the new Chairman of the Board of Directors Basel, Switzerland, 23 April 2021 - At today's Annual General Meeting of Medartis Holding AG (SIX: MED), shareholders approved all the proposals of the Board of Directors by a large majority and elected Marco Gadola as the new Chairman of the Board of Directors. He succeeds Dr. h.c. Thomas Straumann, who will assume the role of Vice Chairman.

At today's Annual General Meeting of Medartis Holding AG, which took place without shareholders being physically present at the event due to the Covid-19 situation, 9'426'464 shares were represented, corresponding to 80% of total share capital.

All existing members of the Board of Directors - Dr. h.c. Thomas Straumann, Marco Gadola, Dominik Ellenrieder, Dr. J?rg Greuter, Dr. med. Daniel Herren, Roland Hess, Willi Miesch and Damien Tappy - were re-elected for a further term of office of one year. Marco Gadola was newly elected as Chairman of the Board of Directors for the next one-year term.

Dr. h.c. Thomas Straumann, who founded Medartis in 1997, stated: "After 23 years, I am very pleased to place the chairmanship of the Board of Directors on a very solid basis in the capable hands of Marco Gadola. I wish him all the best and every success as Chairman of the Board of Directors of our company. I personally remain committed to Medartis over the long term as a significant shareholder and as Vice Chairman of the Board of Directors."

Marco Gadola, the new Chairman of the Board of Directors of Medartis, commented: "I would like to thank shareholders for electing me and for the trust they have placed in me. In my role as Chairman, I will work with the Board of Directors and the Executive Management Board to establish Medartis as a leading comprehensive solutions provider for the extremities and the head, with a broad international presence. I am also passionate about further evolving our strong corporate culture as an important component of Medartis' success."

Shareholders further approved the Management Report, the Annual Financial Statements and the Consolidated Financial Statements 2020. A dividend will not be distributed for the 2020 financial year. In addition, shareholders granted discharge to the members of the Board of Directors for their activities during the 2020 financial year and approved the agenda items relating to compensation.

More detailed information as well as the voting results for the individual agenda items can be found on Medartis' website at Investor & Media Relations or at the following link.

The next Annual General Meeting will be held on 06 April 2022.

Contact Patrick Christ Head Corporate Services Medartis Holding AG Phone: +41 61 633 34 70patrick.christ@medartis.com

About Medartis Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs over 640 individuals across its 14 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best in class service. For more information, please visit www.medartis.com.

Disclaimer This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.

End of ad hoc announcement Language: English Company: Medartis Holding AG Hochbergerstrasse 60E 4057 Basel

Switzerland Phone: +41 61 633 34 34 Fax: +41 61 633 34 00 E-mail: info@medartis.com Internet: www.medartis.com ISIN: CH0386200239 Valor: 38620023 Listed: SIX Swiss Exchange EQS News ID: 1187932 ? End of Announcement EQS Group News Service

1187932??23-Apr-2021?CET/CEST

@ dgap.de